Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies - 101793

Spotlight
Video

Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies

VJHemOnc has 918 videos Subscribe Here

Loading........
Description: Immune checkpoint inhibitors and T-cell engaging bi-specific antibodies have shown promising activity against lymphoid malignancies. In this interview, Anthony Mato, MD, MSCE, of the University of Pennsylvania, Philadelphia, PA, discusses the open-label, multicenter study of REGN2810 alone or in combination with REGN1979 in patients with B-lymphoid malignancies (NCT02651662). This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Shared By : VJHemOnc
Posted on : 02/02/18
Added : 18 days ago



Recommended

Nothing found.

More From VJHemOnc

Nothing found.